Pfenex Inc (PFNX)
Pfenex is a development and licensing biotechnology company focused on utilizing its proprietary protein production platform, Pfenex Expression Technology®, to develop protein therapeutics to improve existing therapies and create therapies for diseases still waiting to be addressed. The U.S. Food and Drug Administration-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture. Co.'s other product includes PF743 (JZP-458), which it is developing in collaboration with Jazz Pharmaceuticals Ireland Limited for the treatment of acute lymphoblastic leukemia. Co. has added PF810, a peptide based therapeutic, to its wholly owned pipeline.
|
March 29, 2024 10:22 AM Eastern
Hold (2.40 out of 4)
100th percentile
|
|